HIV enters deep sleep in people who naturally control the virus

Our ability to keep HIV under control has been revolutionized by antiretroviral therapy (ART). But ART is not a cure — the HIV genome can integrate into host DNA and hide out in cells in a silent form, even after decades of successful therapy13. ART must be continued throughout life, to prevent the virus from rebounding from these viral reservoirs. Could ways to prevent this viral rebound be found by studying the small proportion (less than 0.5%) of people living with HIV who can control viral replication without the need for ART? Writing in Nature, Jiang et al.4 compared the viral reservoirs of these individuals, known as elite controllers, with those of people who are prescribed ART. Their findings suggest that elite control is associated with a small reservoir from which HIV is unlikely to be reactivated.

The authors began by using a sophisticated sequencing technique to compare viral genomes (proviruses) in millions of cells from the two groups of people. As expected, the comparison revealed fewer copies of the HIV genome in elite controllers than in people receiving ART. However, a higher proportion of the proviruses found in controllers were genetically intact — meaning that they have the potential to generate infectious viral particles when transcribed.

Jiang et al. frequently observed many identical copies of the viral genome in elite controllers. This observation confirms5 that infected cells have the ability to proliferate in controllers, as they do in people receiving ART68. Elite controllers are known9 to mount a potent immune response against HIV-infected cells, and the authors found that the proviral sequences persisting in elite controllers were predicted to generate viral proteins that could be targeted by this response.

How, then, do these proviruses escape the immune response? To answer this question, the authors made use of a recently developed approach10 to analyse the sites at which viruses have integrated into the host genome, in conjunction with corresponding proviral sequences. The analysis revealed several characteristics that suggest that the proviruses found in elite controllers are in a deeper state of latency (dormancy) than are the proviruses in people treated with ART.

First, proviruses in elite controllers are more likely to be integrated in non-protein-coding regions of the genome. Second, viral genomes from controllers are frequently positioned in, or surrounded by, repetitive stretches of DNA at chromosomal structures called centromeres. The host genome is packaged into a DNA–protein complex called chromatin — at centromeres, this packaging is unusually dense, which strongly represses transcription. Third, a substantial portion of HIV genomes in elite controllers are integrated in genes that encode members of the zinc-finger protein family, at which chromatin notoriously carries many molecular modifications that are associated with transcriptional repression11.

The authors also performed an analysis of accessible chromatin regions (those at which transcription is possible), which revealed that virus-integration sites in the DNA of elite controllers are located significantly farther from accessible chromatin than those in ART-treated individuals. This result reinforces the idea that the genomes of elite controllers are less likely to actively produce viral transcripts and proteins. Indeed, intact proviruses in elite controllers produced ten times fewer viral transcripts than did HIV genomes from people receiving ART.

Two scenarios could explain the peculiar proviral landscape of elite controllers. First, HIV integration could preferentially occur in particular regions of the genomes in these individuals. Alternatively, the proviruses that integrate into non-coding or transcriptionally repressed regions could be selected over time, with those that are more permissive to viral transcription being eliminated.

Definitively distinguishing between these two possibilities would require researchers to follow elite controllers over a long period of time, which was not within the scope of the current study. However, when Jiang et al. infected cells from elite controllers and people receiving ART with HIV in vitro, they found no significant difference in the integration patterns between the two, making the first scenario unlikely. The second model is also attractive because of the unusually potent immune responses against HIV-infected cells frequently observed in elite controllers. These responses might gradually eliminate the provirus-containing cells that are more likely to produce viral proteins (Fig. 1). Such selection could, over years, result in a reservoir made entirely of proviruses that are unlikely to be reactivated.

Figure 1

Figure 1 | Selection of sleeping HIV in elite controllers. A small proportion of people living with HIV can control the virus without antiretroviral therapy (ART). Jiang et al.4 provide evidence that the viral DNA in these elite controllers is integrated across the host genome. Some viral genomes become integrated at places in which host DNA is loosely packaged with proteins in a complex called chromatin, meaning that transcription can occur. Other viral DNA is integrated at host sites where transcription is repressed because chromatin packaging is dense. Cells that transcribe the virus (generating viral messenger RNA and proteins) are efficiently targeted by immune T cells — a response seen only in elite controllers. These cells are killed, and so a small pool of cells harbouring deeply latent HIV genomes is evolutionarily selected over time.

This idea is supported by previous work12 indicating that the pool of replication-competent virus is extremely small in elite controllers. Furthermore, one participant in Jiang and colleagues’ study had no detectable replication-competent HIV at all, even though the authors thoroughly analysed more than one billion cells from this person. Whether HIV has been completely eradicated from this individual’s body will be hard to demonstrate, but their case is certainly reminiscent of previous reports of HIV cure13,14.

Elite controllers represent only a small proportion of people living with HIV. Nonetheless, Jiang and colleagues’ work has several implications for the rest of this population. It suggests that deeply latent proviruses could preferentially persist after years of viral suppression with ART, particularly in individuals who have maintained immune responses against HIV. Perhaps continuous immune pressure over years would select a small reservoir from which HIV replication would be less likely to reignite. But whether deep-sleeping viral genomes could be reactivated and contribute to viral rebound during ART interruption remains to be determined.

Either way, the results of this study imply that both the intactness and the activation potential of viral genomes should be assessed when measuring the magnitude of the persistent HIV reservoir that can cause viral rebound. Assays that are currently used to estimate the size of the viral reservoir generally measure either the number of intact HIV genomes or their ability to generate RNA or proteins in vitro. Jiang and colleagues’ work suggests that combining both measures could be necessary, because many intact genomes might not be easily reactivated. A combination measure could provide researchers and clinicians with a better predictor of viral rebound following ART interruption.

The study indicates that a continuous and prolonged cellular-immune pressure might substantially reduce the size of the HIV reservoir over time, by selecting a small pool of cells containing hard-to-reactivate HIV genomes. This, in turn, suggests that immune-cell therapies — including therapies based on CAR T cells, which are currently being developed to control HIV reservoirs15 — might not only control viral rebound during ART interruption, but also shrink the viral reservoir to a pool of deeply latent proviruses. Whether this could result in a long-term remission of HIV infection remains, of course, to be determined.

Nature 585, 190-191 (2020)

doi: https://doi.org/10.1038/d41586-020-02438-7


  1. 1.

    Finzi, D. et al. Science 278, 1295–1300 (1997).

    PubMed  Article  Google Scholar 

  2. 2.

    Wong, J. K. et al. Science 278, 1291–1295 (1997).

    PubMed  Article  Google Scholar 

  3. 3.

    Chun, T. W. et al. Proc. Natl Acad. Sci. USA 94, 13193–13197 (1997).

    PubMed  Article  Google Scholar 

  4. 4.

    Jiang, C. et al. Nature 585, 261–267 (2020).

    Article  Google Scholar 

  5. 5.

    Boritz, E. A. et al. Cell 166, 1004–1015 (2016).

    PubMed  Article  Google Scholar 

  6. 6.

    Wagner, T. A. et al. Science 345, 570–573 (2014).

    PubMed  Article  Google Scholar 

  7. 7.

    Maldarelli, F. et al. Science 345, 179–183 (2014).

    PubMed  Article  Google Scholar 

  8. 8.

    Simonetti, F. R. et al. Proc. Natl Acad. Sci. USA 113, 1883–1888 (2016).

    PubMed  Article  Google Scholar 

  9. 9.

    Migueles, S. A. et al. Immunity 29, 1009–1021 (2008).

    PubMed  Article  Google Scholar 

  10. 10.

    Einkauf, K. B. J. Clin. Invest. 129, 988–998 (2019).

    PubMed  Article  Google Scholar 

  11. 11.

    Vogel, M. J. et al. Genome Res. 16, 1493–1504 (2006).

    PubMed  Article  Google Scholar 

  12. 12.

    Blankson, J. N. et al. J. Virol. 81, 2508–2518 (2007).

    PubMed  Article  Google Scholar 

  13. 13.

    Hutter, G. et al. N. Engl. J. Med. 360, 692–698 (2009).

    PubMed  Article  Google Scholar 

  14. 14.

    Gupta, R. K. et al. Nature 568, 244–248 (2019).

    PubMed  Article  Google Scholar 

  15. 15.

    Herzig, E. et al. Cell 179, 880–894.e10 (2019).

    PubMed  Article  Google Scholar 

Download references


Nature Briefing

An essential round-up of science news, opinion and analysis, delivered to your inbox every weekday.

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing